Literature DB >> 12431023

Ambrisentan (Myogen).

George E Billman1.   

Abstract

Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By August 2001, ambrisentan had entered phase II trials for chronic heart failure, hypertension, kidney failure and pulmonary hypertension.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12431023

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  6 in total

Review 1.  Ambrisentan: a review of its use in pulmonary arterial hypertension.

Authors:  Belinda N Rivera-Lebron; Michael G Risbano
Journal:  Ther Adv Respir Dis       Date:  2017-04-20       Impact factor: 4.031

Review 2.  Drug treatment of pulmonary arterial hypertension: current and future agents.

Authors:  Marius M Hoeper
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Adjunct ambrisentan therapy had clinical benefits in 5 dogs with sildenafil-refractory pulmonary hypertension.

Authors:  Seijirow Goya; Tomohiko Yoshida; Shigeharu Sennba; Tsuyoshi Uchide; Ryou Tanaka
Journal:  Can Vet J       Date:  2022-05       Impact factor: 1.075

4.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 5.  A review of pulmonary arterial hypertension: role of ambrisentan.

Authors:  Robyn J Barst
Journal:  Vasc Health Risk Manag       Date:  2007

Review 6.  The limits of oral therapy in pulmonary arterial hypertension management.

Authors:  Qian-Qian Liu; Zhi-Cheng Jing
Journal:  Ther Clin Risk Manag       Date:  2015-11-23       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.